A share price of Humacyte Inc [HUMA] is currently trading at $1.45, down -13.69%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The HUMA shares have lost -5.23% over the last week, with a monthly amount drifted -54.40%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Humacyte Inc [NASDAQ: HUMA] stock has seen the most recent analyst activity on December 20, 2024, when H.C. Wainwright reiterated its Buy rating and also boosted its price target to $15 from $12. Previously, H.C. Wainwright started tracking the stock with Buy rating on December 11, 2023, and set its price target to $6. On August 14, 2023, upgrade upgraded it’s rating to Neutral and revised its price target to $3.50 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $6 on June 22, 2023. Piper Sandler downgraded its rating to a Underweight and reduced its price target to $4 on May 16, 2022. Cowen started tracking with a Outperform rating for this stock on October 29, 2021, and assigned it a price target of $17. In a note dated September 24, 2021, Oppenheimer initiated an Outperform rating and provided a target price of $16 on this stock.
Humacyte Inc experienced fluctuations in its stock price throughout the past year between $1.15 and $9.97. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Humacyte Inc [NASDAQ: HUMA] shares were valued at $1.45 at the most recent close of the market. An investor can expect a potential return of 382.76% based on the average HUMA price forecast.
Analyzing the HUMA fundamentals
An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.31.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.3736 points at the first support level, and at 1.2972 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.5928, and for the 2nd resistance point, it is at 1.7356.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Humacyte Inc [NASDAQ:HUMA] is 2.40. In addition, the Quick Ratio stands at 2.40 and the Cash Ratio stands at 2.25.
Transactions by insiders
Recent insider trading involved Scheessele William John, Chief Commercial Officer, that happened on Apr 14 ’25 when 6493.0 shares were purchased. CFO and Chief Corp. Deve. Off., Sander Dale A. completed a deal on Apr 10 ’25 to buy 20000.0 shares. Meanwhile, Chief Medical Officer Parikh Shamik J bought 7500.0 shares on Apr 10 ’25.
